about
Efficacy and safety of ablation for patients with non-paroxysmal atrial fibrillationAntiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillationAntiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillationAntiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillationAtrial fibrillation in heart failure: what should we do?Dronedarone-current status in management of atrial fibrillation2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society.Rationale and current perspective for early rhythm control therapy in atrial fibrillation.The current approach of atrial fibrillation managementCost-Effectiveness of Cardiac Radiosurgery for Atrial Fibrillation: Implications for Reducing Health Care Morbidity, Utilization, and Costs.2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of theDrug therapy for atrial fibrillationUse of statins and antihypertensive medications in relation to risk of long-standing persistent atrial fibrillationWho Needs Pharmacologic Therapy?Targeted deep sequencing reveals no definitive evidence for somatic mosaicism in atrial fibrillation.A placebo-controlled, double-blind, randomized, multicenter study to assess the effects of dronedarone 400 mg twice daily for 12 weeks on atrial fibrillation burden in subjects with permanent pacemakers.Personalized management of atrial fibrillation: Proceedings from the fourth Atrial Fibrillation competence NETwork/European Heart Rhythm Association consensus conference.Rate Versus Rhythm Control Pharmacotherapy For Atrial Fibrillation: Where are We in 2008?Atrial Fibrillation Complicating Congestive Heart Failure: Electrophysiological Aspects And Its Deleterious Effect On Cardiac Resynchronization TherapyThe economics of comparative effectiveness studies: societal and private perspectives and their implications for prioritizing public investments in comparative effectiveness researchSerological predictors for the recurrence of atrial fibrillation after electrical cardioversion.Impact of the control of symptomatic paroxysmal atrial fibrillation on health-related quality of life.Antiarrhythmic drugs for atrial fibrillation.Prevalence of amiodarone-induced thyrotoxicosis and associated risk factors in Japanese patients.Atrial fibrillation in congestive heart failure.Use of antiarrhythmic drug therapy and clinical outcomes in older patients with concomitant atrial fibrillation and coronary artery disease.Present concepts in management of atrial fibrillation: From drug therapy to ablation.RHYTHM-AF: design of an international registry on cardioversion of atrial fibrillation and characteristics of participating centers.Bramah N. Singh, MD, DPhil, DSc: A Tribute.Influence of age, sex, and atrial fibrillation recurrence on quality of life outcomes in a population of patients with new-onset atrial fibrillation: the Fibrillation Registry Assessing Costs, Therapies, Adverse events and Lifestyle (FRACTAL) study.Comparison of rate control and rhythm control in patients with atrial fibrillation after percutaneous mitral balloon valvotomy: a randomised controlled study.Rhythm control and cardioversionAmiodarone-associated optic neuropathy: a critical review.Amiodarone use is associated with increased risk of stroke in patients with nonvalvular atrial fibrillation: a nationwide population-based cohort study.The future of atrial fibrillation therapy.Dronedarone: an emerging agent with rhythm- and rate-controlling effects.Medical management of atrial fibrillation: state of the art.Management of atrial fibrillation: focus on the role of dronedarone.Amiodarone and risk of death in contemporary patients with atrial fibrillation: Findings from The Retrospective Evaluation and Assessment of Therapies in AF study.Sex differences in the relationship between amiodarone use and the need for permanent pacing in patients with atrial fibrillation.
P2860
Q24186195-07AA1ECE-8F78-44F6-9F0F-909F3995BF7FQ24187110-F07A79AD-985B-4E37-9D26-258C7BAAE01FQ24197643-4C9DA9AF-8593-4F41-A194-69314113D870Q24243067-9A42D593-1692-4516-A15B-D87D411A219BQ26784426-6D919DB1-8BFC-48DC-9376-F903910F526EQ27001666-9CFCB2E6-97BF-4137-AD45-AD9DB81CB0E3Q27341873-7DAC2AD8-698C-41FE-91DB-53F554B248EAQ27692632-8C9F0309-CBD5-4AF2-831D-386E1AE924DCQ28076171-06760AC8-F32D-4F34-BAB9-DB557A3B7BC1Q28077393-246322B9-5C27-462B-B1C5-9B6BC8BB1B73Q28087002-9A325AE2-5A95-46AC-8C82-EEBC660101F4Q28218580-0E45243D-9D3F-44FE-9731-B3171B6DCA47Q28607864-B61D6058-90D6-475E-8B25-0CF5D6AB14F1Q30354838-3A32A340-13D4-4A99-9794-8AE1E9B47D63Q30392171-CC502BAE-9A69-4EA5-934F-AF78B90F5CB2Q30407585-3B7C0B56-EE66-4C0F-A87F-F705D2D1A29DQ30663685-2D70AC1B-4AD0-4BB3-B1CA-54CB80074BBAQ33585592-84AD0069-9FF5-479C-8D42-1C6447E53F49Q33585671-83242FDD-AB68-4E94-B5FA-439BB302924FQ33622655-4494BBB6-92D0-4E85-9B97-CAB358545AADQ33809189-AA57072D-EE6D-4039-8F0A-C4F878197D34Q33811334-3D77C9AA-F87E-471F-9466-3014968D3B9CQ33821199-4446EFD0-E377-4EB8-83E8-DBE94C8CC2EDQ33905666-F25AA6BA-3C77-474E-96C8-11E616185B0FQ33954432-69BC0005-FA6E-4198-83BB-F6FFB879661CQ34169705-EAC680DE-3E1C-44C7-90BC-5FD05CEDB656Q34389483-CC53F1F0-BD8F-4548-968D-35E7924063C2Q34432030-41F58D17-25FE-4AF4-83B3-01482262EC2CQ34465502-2754C269-03FD-414D-B851-68207C351635Q35677114-138E3D39-1233-4605-AB8D-1C6D9901A43EQ35772220-BAC3D174-A2DC-4559-9E80-C8C124CFCE42Q35772996-0D2CEEBC-2413-4FFD-BB91-BC12399D420EQ35878060-25525B71-11A1-4A1A-B2F9-CC7353FC9773Q36151596-E9950FE7-5182-4D72-BF7C-4E5E61C84C35Q36580659-247BBC8D-E72C-479B-8B71-B749FFA614CEQ36580662-4E1E746E-BB00-463A-9C38-B7F0C78060C2Q36580667-D055405C-327D-4E88-9BD0-27A5B4BE5F3AQ36581235-6891A9F7-8234-42BF-913A-FD1EBB7032CEQ36709675-DFB68B6E-C5DC-43B3-B6CC-BAA880B1FA0EQ36713626-931278DE-FCBD-41E1-903C-1210F82C232B
P2860
description
2005 nî lūn-bûn
@nan
2005 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Amiodarone versus sotalol for atrial fibrillation.
@ast
Amiodarone versus sotalol for atrial fibrillation.
@en
Amiodarone versus sotalol for atrial fibrillation.
@nl
type
label
Amiodarone versus sotalol for atrial fibrillation.
@ast
Amiodarone versus sotalol for atrial fibrillation.
@en
Amiodarone versus sotalol for atrial fibrillation.
@nl
prefLabel
Amiodarone versus sotalol for atrial fibrillation.
@ast
Amiodarone versus sotalol for atrial fibrillation.
@en
Amiodarone versus sotalol for atrial fibrillation.
@nl
P2093
P356
P1476
Amiodarone versus sotalol for atrial fibrillation.
@en
P2093
Alan K Jacobson
Becky Lopez
Bramah N Singh
Crystal L Harris
Dennis W Raisch
Domenic J Reda
H Daniel Lewis
J Edwin Atwood
Michael D Ezekowitz
Ross D Fletcher
P304
P356
10.1056/NEJMOA041705
P407
P577
2005-05-01T00:00:00Z